Respuestas clínicas Cochrane
- In people with chronic obstructive pulmonary disease, what are the effects of integrated disease management interventions?
- How does umeclidinium bromide compare with placebo for people with chronic obstructive pulmonary disease (COPD)?
- How does long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) compare with LABA plus inhaled corticosteroid (ICS) for people with stable chronic obstructive pulmonary disease (COPD)?
- How does tiotropium compare with ipratropium bromide for people with chronic obstructive pulmonary disease (COPD)?
- What are the longer-term (>6 months) effects of inhaled corticosteroids in people with stable chronic obstructive pulmonary disease?
- What are the effects of long‐acting inhaled therapies for adults with chronic obstructive pulmonary disease (COPD)?
- In people with chronic obstructive pulmonary disease (COPD), what are the effects of combined corticosteroid and long-acting beta-agonist (LABA) in one inhaler versus LABA alone?
- What are the effects of influenza vaccine in people with chronic obstructive pulmonary disease (COPD)?
- For people with chronic bronchitis or chronic obstructive pulmonary disease, how do mucolytic agents compare with placebo?
- What are the effects of pulmonary rehabilitation after exacerbation in people with chronic obstructive pulmonary disease?
- How does bronchoscopic lung volume reduction compare with medical therapy in people with chronic obstructive pulmonary disease?
- How does combined aclidinium/formoterol compare with aclidinium or formoterol monotherapy for people with chronic obstructive pulmonary disease (COPD)?
- How does lung volume reduction surgery compare with usual medical care in people with diffuse emphysema?
- What are the effects of prophylactic antibiotics for people with chronic obstructive pulmonary disease (COPD)?
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad